Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment ; volume:7 ; number:1 ; day:12 ; month:7 ; year:2017 ; pages:1-13 ; date:12.2017
Scientific reports ; 7, Heft 1 (12.7.2017), 1-13, 12.2017
- Urheber
-
Chen, Aiping
- Beteiligte Personen und Organisationen
-
Zhang, Yonghui
Meng, Gang
Jiang, Dengxu
Zhang, Hailin
Zheng, Meihong
Xia, Mao
Jiang, Aiqin
Wu, Junhua
Beltinger, Christian
Wei, Jiwu
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-05500-z
- URN
-
urn:nbn:de:101:1-2018080901360580474484
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Aiping
- Zhang, Yonghui
- Meng, Gang
- Jiang, Dengxu
- Zhang, Hailin
- Zheng, Meihong
- Xia, Mao
- Jiang, Aiqin
- Wu, Junhua
- Beltinger, Christian
- Wei, Jiwu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts
MicroRNA-sensitive oncolytic measles virus vectors for chemovirotherapy of pancreatic cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts
MicroRNA-sensitive oncolytic measles virus vectors for chemovirotherapy of pancreatic cancer
Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Advances in antitumour therapy with oncolytic herpes simplex virus combinations
Engineering targeted and cytokine-armed oncolytic measles viruses
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
BiTE-armed oncolytic measles viruses for cancer immunovirotherapy
Key parameters of measles virus production for oncolytic virotherapy
Analysis of primary resistance phenomena to oncolytic measles vaccine virus
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus
Versatility of DARPin-targeted oncolytic measles viruses : safety, efficacy, and specificity
Armed oncolytic measles vaccine virus for the treatment of hepatocellular carcinoma
Oncolytic measles virus MV-NIS controls relapsed pediatric ALL patient-derived xenografts